WO2003068156A3 - Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome - Google Patents

Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome Download PDF

Info

Publication number
WO2003068156A3
WO2003068156A3 PCT/US2003/004137 US0304137W WO03068156A3 WO 2003068156 A3 WO2003068156 A3 WO 2003068156A3 US 0304137 W US0304137 W US 0304137W WO 03068156 A3 WO03068156 A3 WO 03068156A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
inhibiting
treating
post
chronic fatigue
Prior art date
Application number
PCT/US2003/004137
Other languages
French (fr)
Other versions
WO2003068156A2 (en
Inventor
Ritchie Shoemaker
H Kenneth Hudnell
Original Assignee
Ritchie Shoemaker
H Kenneth Hudnell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ritchie Shoemaker, H Kenneth Hudnell filed Critical Ritchie Shoemaker
Priority to AU2003230552A priority Critical patent/AU2003230552A1/en
Publication of WO2003068156A2 publication Critical patent/WO2003068156A2/en
Publication of WO2003068156A3 publication Critical patent/WO2003068156A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses methods of treating or inhibiting one or more of sick building syndrome (SBS), post-Lyme Disease Syndrome (PLDS), and chronic fatigue syndrome (CFS) by administering to a patient in need thereof an amount effective of cholestyramine and/or α-melanocyte stimulating hormone to treat or inhibit one or more of these syndromes.
PCT/US2003/004137 2002-02-13 2003-02-10 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome WO2003068156A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003230552A AU2003230552A1 (en) 2002-02-13 2003-02-10 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35653902P 2002-02-13 2002-02-13
US35644302P 2002-02-13 2002-02-13
US60/356,539 2002-02-13
US60/356,443 2002-02-13

Publications (2)

Publication Number Publication Date
WO2003068156A2 WO2003068156A2 (en) 2003-08-21
WO2003068156A3 true WO2003068156A3 (en) 2004-02-26

Family

ID=27737537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004137 WO2003068156A2 (en) 2002-02-13 2003-02-10 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome

Country Status (3)

Country Link
US (1) US20030219400A1 (en)
AU (1) AU2003230552A1 (en)
WO (1) WO2003068156A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044906A2 (en) * 2005-10-11 2007-04-19 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
EP2061497A1 (en) * 2006-09-14 2009-05-27 Mondobiotech Laboratories AG Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
US9770170B2 (en) * 2012-08-07 2017-09-26 Ritchie Shoemaker Methods for diagnosing, treating, and monitoring chronic inflammatory response syndrome
RU2589694C1 (en) * 2015-05-12 2016-07-10 Екатерина Александровна Диброва Method for preventing and treating chronic fatigue syndrome
US10245284B2 (en) * 2015-08-19 2019-04-02 Alpex Pharma S.A. Granular composition for oral administration
US20180246095A1 (en) * 2015-08-19 2018-08-30 The Johns Hopkins University Compositions and methods for diagnosing and treating lyme disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] SHOEMAKER ET AL.: "Possible estuary-associated syndrome: symptoms, vision and treatment", XP002971476, accession no. NCBI Database accession no. 11401768 *
ENVIRON. HEALTH PERSPECT., vol. 109, no. 5, May 2001 (2001-05-01), pages 539 - 545 *

Also Published As

Publication number Publication date
WO2003068156A2 (en) 2003-08-21
US20030219400A1 (en) 2003-11-27
AU2003230552A1 (en) 2003-09-04
AU2003230552A8 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
CY1108217T1 (en) METHOD OF ADMINISTRATION OF BUPRENORFINE FOR DEPARTMENT TREATMENT
WO2004006906A3 (en) Methods for the treatment of neoplasms
WO2003057666A3 (en) Inhibitors of dipeptidyl peptidase iv
NO20061325L (en) Combination of drugs for the treatment of neoplasms
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
EP1374875A3 (en) Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
WO2004045507A3 (en) Anti-angiogenic uses of il-6 antagonists
WO2006048450A3 (en) Peptides for use in the treating obesity
WO2006048452A3 (en) Peptides for use in treating of obesity
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2005020908A3 (en) Selective inhibitors of stat-3 activation and uses thereof
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
WO2007031853A3 (en) Therapeutic combination of hamlet and a hdac inhibitor to treat cancer
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
WO2006032053A3 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP